Zhimeng Biopharma is a startup biotech founded in 2017 by seasoned pharmaceutical industry veterans. Located in the economy-vibrant and resource-rich Zhangjiang High-Tech Park of Shanghai, China, Zhimeng is developing medicines for the treatment of chronic hepatitis B (CHB) and related liver diseases. Realizing the complexity of the etiologies of liver diseases, Zhimeng has adopted a comprehensive approach to tackle the diseases by directly hitting the hepatitis B virus (HBV) with multiple pronged attacks, as well as restoring the host immune systems. Our mission is to deliver innovative, effective, safe and affordable therapies to bring a cure for patients suffering from CHB and improve the quality of life of patients with other liver diseases.